Published Online
on September 2, 2003

A more recent version of this article appeared on September 30, 2003

This Article Full Text (PDF) All Versions of this Article: 108/13/1626    most recent 01.CIR.0000089371.11664.27v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yue, Y. Articles by Duan, D. Search for Related Content PubMed PubMed Citation Articles by Yue, Y. Articles by Duan, D. Related Collections Gene therapy

Submitted on March 26, 2003
Revised on June 4, 2003
Accepted on June 6, 2003

Microdystrophin Gene Therapy of Cardiomyopathy Restores Dystrophin-Glycoprotein Complex and Improves Sarcolemma Integrity in the Mdx Mouse Heart

Yongping Yue BA, Zhenbo Li PhD, Scott Q. Harper PhD, Robin L. Davisson PhD, Jeffrey S. Chamberlain PhD, and Dongsheng Duan PhD^*

From the Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Mo (Y.Y., D.D.); the Department of Anatomy and Cell Biology, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa (Z.L., R.L.D.); and the Department of Neurology, The University of Washington School of Medicine, Seattle, Wash (S.Q.H., J.S.C.).

^* To whom correspondence should be addressed. E-mail: duand{at}missouri.edu.

Background--More than 90% of Duchenne muscular dystrophy (DMD) patients develop cardiomyopathy, and many die of cardiac failure. Despite tremendous progress in skeletal muscle gene therapy, few attempts have been made to treat cardiomyopathy. Microdystrophin genes are shown to correct skeletal muscle pathological lesions in the mdx mouse model for DMD. Here, we tested the therapeutic potential of adeno-associated virus (AAV)-mediated microdystrophin gene therapy in the mdx mouse heart.

Methods and Results--AAV was delivered to the newborn mdx mouse cardiac cavity. The procedure was rapid and well tolerated. Efficient expression was achieved in the inner and the outer layers of the myocardium. The ubiquitous cytomegalovirus promoter resulted in substantially higher expression than the muscle-specific CK6 promoter. The therapeutic effects of microdystrophin were evaluated at 10 months after infection. Immunostaining demonstrated extensive microdystrophin expression and successful restoration of the dystrophin-glycoprotein complex. Importantly, AAV-mediated microdystrophin expression improved the sarcolemma integrity in the mdx heart.

Conclusions--We established a simple gene transfer method for efficient and persistent transduction of the mdx mouse heart. AAV-mediated microdystrophin expression restored the critical dystrophin-glycoprotein complex and improved sarcolemma integrity of the mdx heart. Our results revealed the promise of AAV-microdystrophin gene therapy for cardiomyopathy in DMD.

Key words: muscular dystrophy • genes • viruses • gene therapy • microdystrophin

This article has been cited by other articles:

				D. Merrick, L. K. J. Stadler, D. Larner, and J. Smith Muscular dystrophy begins early in embryonic development deriving from stem cell loss and disrupted skeletal muscle formation Dis. Model. Mech., July 1, 2009; 2(7-8): 374 - 388. [Abstract] [Full Text] [PDF]

				M. Periasamy and J. A. Rafael-Fortney Somatic gene therapy to treat heart failure is one step closer to reality Cardiovasc Res, June 1, 2009; 82(3): 383 - 384. [Full Text] [PDF]

				D. Li, C. Long, Y. Yue, and D. Duan Sub-physiological sarcoglycan expression contributes to compensatory muscle protection in mdx mice Hum. Mol. Genet., April 1, 2009; 18(7): 1209 - 1220. [Abstract] [Full Text] [PDF]

				D. Li, Y. Yue, and D. Duan Preservation of Muscle Force in Mdx3cv Mice Correlates with Low-Level Expression of a Near Full-Length Dystrophin Protein Am. J. Pathol., May 1, 2008; 172(5): 1332 - 1341. [Abstract] [Full Text] [PDF]

				C. Jung, A. S. Martins, E. Niggli, and N. Shirokova Dystrophic cardiomyopathy: amplification of cellular damage by Ca2+ signalling and reactive oxygen species-generating pathways Cardiovasc Res, March 1, 2008; 77(4): 766 - 773. [Abstract] [Full Text] [PDF]

				B. Bostick, Y. Yue, C. Long, and D. Duan Prevention of Dystrophin-Deficient Cardiomyopathy in Twenty-One-Month-Old Carrier Mice by Mosaic Dystrophin Expression or Complementary Dystrophin/Utrophin Expression Circ. Res., January 4, 2008; 102(1): 121 - 130. [Abstract] [Full Text] [PDF]

				D. Duan Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy Hum. Mol. Genet., October 15, 2006; 15(suppl_2): R253 - R261. [Abstract] [Full Text] [PDF]

				T. Zhu, L. Zhou, S. Mori, Z. Wang, C. F. McTiernan, C. Qiao, C. Chen, D. W. Wang, J. Li, and X. Xiao Sustained Whole-Body Functional Rescue in Congestive Heart Failure and Muscular Dystrophy Hamsters by Systemic Gene Transfer Circulation, October 25, 2005; 112(17): 2650 - 2659. [Abstract] [Full Text] [PDF]

				M.W. Ashford Jr, W. Liu, S.J. Lin, P. Abraszewski, S.D. Caruthers, A.M. Connolly, X. Yu, and S.A. Wickline Occult Cardiac Contractile Dysfunction in Dystrophin-Deficient Children Revealed by Cardiac Magnetic Resonance Strain Imaging Circulation, October 18, 2005; 112(16): 2462 - 2467. [Abstract] [Full Text] [PDF]

				Y. Yue, J. W. Skimming, M. Liu, T. Strawn, and D. Duan Full-length dystrophin expression in half of the heart cells ameliorates {beta}-isoproterenol-induced cardiomyopathy in mdx mice Hum. Mol. Genet., August 1, 2004; 13(15): 1669 - 1675. [Abstract] [Full Text] [PDF]

				K. A. Lapidos, R. Kakkar, and E. M. McNally The Dystrophin Glycoprotein Complex: Signaling Strength and Integrity for the Sarcolemma Circ. Res., April 30, 2004; 94(8): 1023 - 1031. [Abstract] [Full Text] [PDF]